Candel Therapeutics, Inc. CADL Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $36.32M+19.1% | $30.5M+25.6% | $24.29M+14.3% | $21.24M+10.5% | $19.23M-0.4% | ||
| $20.1M+13.1% | $17.77M+8.6% | $16.37M+9.4% | $14.97M+4.1% | $14.37M+2.2% | ||
| $56.42M+16.9% | $48.27M+18.7% | $40.66M+12.3% | $36.21M+7.8% | $33.6M+0.7% | ||
| -$56.42M-16.9% | -$48.27M-18.7% | -$40.66M-12.3% | -$36.21M-7.8% | -$33.6M-0.7% | ||
| $3.38M+59.4% | $2.12M+93.9% | $1.09M-23.0% | $1.42M-18.9% | $1.75M-16.3% | ||
| —— | —— | $17.9M+27.2% | $14.07M+335% | -$5.98M+72.6% | ||
| -$54.42M-42.5% | -$38.18M-67.8% | -$22.76M-2.8% | -$22.14M+44.1% | -$39.58M+28.3% | ||
| -$0.99-37.5% | -$0.72-28.6% | -$0.56+17.6% | -$0.68+48.9% | -$1.33+23.6% | ||
| -$55.71M-17.4% | -$47.46M-19.3% | -$39.77M-12.6% | -$35.32M-8.0% | -$32.71M-0.7% | ||
| -$56.42M-16.9% | -$48.27M-18.7% | -$40.66M-12.3% | -$36.21M-7.8% | -$33.6M-0.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Candel Therapeutics, Inc.'s revenue?
- Candel Therapeutics, Inc. (CADL) generated $124.0K in revenue over the trailing twelve months.
- Is Candel Therapeutics, Inc. profitable?
- Candel Therapeutics, Inc. is not currently profitable: it reported a net loss of $54.4M over the trailing twelve months, a -15156.5% net margin.
- What is Candel Therapeutics, Inc.'s earnings per share?
- Candel Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-0.99.
- Where does Candel Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Candel Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
